Skip to main content

Advertisement

SpringerLink
Log in

Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope

  • Lung Cancer (JM Johnson, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Small cell lung cancer (SCLC) is a devastating and aggressive neuroendocrine carcinoma of the lung. It accounts for ~15% of lung cancer mortality and has had no improvement in standard treatment options for nearly 30 years. However, there is now hope for change with new therapies and modalities of therapy. Immunotherapies and checkpoint inhibitors are entering clinical practice, selected targeted therapies show promise, and “smart bomb”-based drug/radioconjugates have led to good response in early clinical trials. Additionally, new research insights into the genetics and tumor heterogeneity of SCLC alongside the availability of new tools such as patient-derived or circulating tumor cell xenografts offer the potential to shine light on this beshadowed cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Codony-Servat J, Verlicchi A, Rosell R. Cancer stem cells in small cell lung cancer. Translational Lung Cancer Research. 2016;5(1):16–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Sarvi S, et al. CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist. Cancer Res. 2014;74(5):1554–65.

    Article  CAS  PubMed  Google Scholar 

  3. Pietanza MC, et al. Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res. 2015;21(10):2244–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. • Network, N.C.C. NCCN Clinical Practice Guidelines in Oncology Small Cell Lung Cancer Version 2.2017. 2016. September 15, 2016 cited 2016 12/9/2016. Includes clinical recommendations involving immunotherapy treatment in the second-line off study for SCLC for the first time.

  5. • Hodi FS, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. The Lancet Oncology. 2016;17(11):1558–68. Landmark study showing improved efficacy of combination checkpoint inhibitor therapy.

    Article  CAS  PubMed  Google Scholar 

  6. Motzer RJ, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13.

    Article  CAS  PubMed  Google Scholar 

  7. • Reck M, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33. Showed for the first time superiority of immunotherapy versus chemotherapy first line in lung cancer. Further supports use of biomarkers, though better biomarkers than PD-L1 alone are needed.

    Article  CAS  PubMed  Google Scholar 

  8. Langer CJ, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. The Lancet Oncology. 2016;17(11):1497–508.

    Article  CAS  PubMed  Google Scholar 

  9. Lowenbraun S, et al. The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma. Cancer. 1979;44(2):406–13.

    Article  CAS  PubMed  Google Scholar 

  10. Chute JP, et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol. 1999;17(6):1794.

    Article  CAS  PubMed  Google Scholar 

  11. Sundstrøm S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up. J Clin Oncol. 2002;20(24):4665–72.

    Article  PubMed  Google Scholar 

  12. Gozzard P, et al. Paraneoplastic neurologic disorders in small cell lung carcinoma: a prospective study. Neurology. 2015;85(3):235–9.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Pieczonka CM, et al. Sipuleucel-T for the treatment of patients with metastatic castrate-resistant prostate cancer: considerations for clinical practice. Reviews in Urology. 2015;17(4):203–10.

    PubMed  PubMed Central  Google Scholar 

  14. Hirschowitz EA, Yannelli JR. Immunotherapy for lung cancer. Proc Am Thorac Soc. 2009;6(2):224–32.

    Article  CAS  PubMed  Google Scholar 

  15. Kim S-K, et al. Impact of minimal tumor burden on antibody response to vaccination. Cancer Immunol Immunother. 2011;60(5):621–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. • Carter L, et al. Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer. Nat Med. 2016. advance online publication. Exciting association with CDXs and correlation with patient profiles and chemoresponsiveness. This brings this model forward and could help lead to better personalized medicine and SCLC modeling.

  17. Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14(8):561–84.

    Article  CAS  PubMed  Google Scholar 

  18. Kvistborg P, et al. Anti–CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med. 2014;6(254):254ra128.

    Article  PubMed  Google Scholar 

  19. Wang W, et al. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25Hi regulatory T cells. Int Immunol. 2009;21(9):1065–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. •• Antonia SJ, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. The Lancet Oncology. 2016;17(7):883–95. Still preliminary but exciting data for efficacy, particularly in combination for SCLC. This study needs further confirmation but opens the door for immunotherapy to change the clinical treatment of SCLC.

    Article  CAS  PubMed  Google Scholar 

  21. • Borghaei H, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39. Practice-changing trial along with #23, brought immunotherapy to lung cancer.

    Article  CAS  PubMed  Google Scholar 

  22. Garon EB, et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28.

    Article  PubMed  Google Scholar 

  23. Herbst RS, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50.

    Article  CAS  PubMed  Google Scholar 

  24. •• George J, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524(7563):47–53. Together, these two articles have brought SCLC into the genetic age with sequencing of 100+ primary SCLC samples and RNAseq. The studies need to be expanded with clinically annotated samples, but these studies built the foundation that is needed to move forward with genetic characterization of this disease.

  25. •• Rudin CM, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012;44(10):1111–6. Together, these two articles have brought SCLC into the genetic age with sequencing of 100+ primary SCLC samples and RNAseq. The studies need to be expanded with clinically annotated samples, but these studies built the foundation that is needed to move forward with genetic characterization of this disease.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Thomas LR, et al. The MYC–WDR5 nexus and cancer. Cancer Res. 2015;75(19):4012–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. • Thomas LR, et al. Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC. Mol Cell. 2015;58(3):440–52. Novel targeting approach for MYC, which is an extremely challenging target and vital for SCLC as well as multiple other tumor types.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Paolo Fiorentino F, et al. Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation. Oncotarget. 2016;7(21):31014–28.

    Google Scholar 

  29. Goldenson B, Crispino JD. The aurora kinases in cell cycle and leukemia. Oncogene. 2015;34(5):537–45.

    Article  CAS  PubMed  Google Scholar 

  30. Glover DM, et al. Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell. 1995;81(1):95–105.

    Article  CAS  PubMed  Google Scholar 

  31. Schoffski P, et al. Efficacy and safety of biweekly i.v. administrations of the aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study. Ann Oncol. 2015;26(3):598–607.

    Article  CAS  PubMed  Google Scholar 

  32. Melichar B, et al. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. The Lancet Oncology. 2015;16(4):395–405.

    Article  CAS  PubMed  Google Scholar 

  33. Helfrich BA, et al. Barasertib (AZD1152), a small molecule aurora B inhibitor, inhibits the growth of SCLC cell lines in vitro and in vivo. Mol Cancer Ther. 2016;15(10):2314–22.

    Article  CAS  PubMed  Google Scholar 

  34. Schneider L, et al. Directional cell migration and chemotaxis in wound healing response to PDGF-AA are coordinated by the primary cilium in fibroblasts. Cell Physiol Biochem. 2010;25(2–3):279–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Lehman JM, et al. The oak ridge polycystic kidney mouse: modeling ciliopathies of mice and men. Dev Dyn. 2008;237(8):1960–71.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Han Y-G, et al. Dual and opposing roles of primary cilia in medulloblastoma development. Nat Med. 2009;15(9):1062–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Wong SY, et al. Primary cilia can both mediate and suppress hedgehog pathway-dependent tumorigenesis. Nat Med. 2009;15(9):1055–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Izawa I, et al. Current topics of functional links between primary cilia and cell cycle. Cilia. 2015;4(1):12.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Ezratty EJ, et al. A role for the primary cilium in notch signaling and epidermal differentiation during skin development. Cell. 2011;145(7):1129–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Grisanti L, et al. Primary cilia maintain corneal epithelial homeostasis by regulation of the notch signaling pathway. Development. 2016;143(12):2160–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Mans DA, Voest EE, Giles RH. All along the watchtower: is the cilium a tumor suppressor organelle? Biochim Biophys Acta. 2008;1786(2):114–25.

    CAS  PubMed  Google Scholar 

  42. Bishop CL, et al. Primary cilium-dependent and -independent hedgehog signaling inhibits p16(INK4A). Mol Cell. 2010;40(4):533–47.

    Article  CAS  PubMed  Google Scholar 

  43. Raleigh D, et al. Hedgehog pathway misactivation induces CDK6 to drive medulloblastoma. International Journal of Radiation Oncology Biology Physics. 2016;96(2):S56.

    Article  Google Scholar 

  44. Park K-S, et al. A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat Med. 2011;17(11):1504–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Dere R, et al. β-Catenin links von Hippel-Lindau to aurora kinase A and loss of primary cilia in renal cell carcinoma. J Am Soc Nephrol. 2015;26(3):553–64.

    Article  CAS  PubMed  Google Scholar 

  46. Pugacheva EN, et al. HEF1-dependent aurora a activation induces disassembly of the primary cilium. Cell. 2007;129(7):1351–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. •• Saunders LR, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015;7(302):302ra136. Very strong preclinical data with excellent long-term response in DLL3+ PDX models, followed by clinical trial below.

    Article  PubMed  PubMed Central  Google Scholar 

  48. • Rudin CM, Pietanza MC, Bauer TM, Spigel DR, Ready N, Morgensztern D, et al. Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC). J Clin Oncol. 2016. 34 (suppl; abstr LBA8505). Now in phase II, excited to see full efficacy of this agent, in appropriate high DLL3-expressing SCLC, has a good preliminary response compared to other agents, particularly in refractory DLL3+ disease which has a very poor prognosis otherwise.

  49. Cerrato A, Morra F, Celetti A. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. J Exp Clin Cancer Res. 2016;35(1):179.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Satoh MS, Lindahl T. Role of poly[ADP-ribose] formation in DNA repair. Nature. 1992;356(6367):356–8.

    Article  CAS  PubMed  Google Scholar 

  51. Murai J, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther. 2014;13(2):433–43.

    Article  CAS  PubMed  Google Scholar 

  52. Murai J, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72(21):5588–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Byers LA, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer discovery. 2012;2(9):798–811.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Pietanza MC, et al. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res. 2012;18(4):1138–45.

    Article  CAS  PubMed  Google Scholar 

  55. Pietanza MC, Krug LM, Waqar SN, Dowlati A, Hann CL, Chiappori A, et al., A multi-center, randomized, double-blind phase II study comparing temozolomide (TMZ) plus either veliparib (ABT-888), a PARP inhibitor, or placebo as 2nd or 3rd-line therapy for patients (Pts) with relapsed small cell lung cancers (SCLCs). J Clin Oncol. 2016. 34 suppl; abstr 8512.

  56. • Cardnell RJ, et al. Activation of the PI3K/mTOR pathway following PARP inhibition in small cell lung cancer. PLoS One. 2016;11(4):e0152584. Novel as an example again, that successful use of targeted therapies in SCLC will likely require additional biomarkers.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Nakajima W, et al. Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer. in Proceedings of the AACR-IASLC joint conference on molecular origins of lung cancer. 2014. San Diego: AACR.

  58. Perciavalle RM, Opferman JT. Delving deeper: MCL-1’s contributions to normal and cancer biology. Trends Cell Biol. 2013;23(1):22–9.

    Article  CAS  PubMed  Google Scholar 

  59. Langer C, et al. A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC). In ASCO annual meeting. 2011. Chicago: ASCO.

  60. Langer C, et al. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer. Lung Cancer. 2014;85(3):420–8.

    Article  PubMed  Google Scholar 

  61. Nguyen M, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci. 2007;104(49):19512–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. • Tse C, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421–8. This agent’s much higher specificity than obatoclax and better toxicity profile suggest that revising these agents in SCLC may be reasonable. Combination therapy also becomes more feasible with the better side effect profile.

    Article  CAS  PubMed  Google Scholar 

  63. Faber AC, et al. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proceedings of the Naitonal Academy of Sciences of the United States of America. 2015;112(11):1288–96.

    Article  Google Scholar 

  64. Nakajima W, et al. Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer. Cancer Biology & Therapy. 2016;17(1):27–35.

    Article  CAS  Google Scholar 

  65. Suk Heist R, et al. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J Thorac Oncol. 2010;5(10):1637–43.

    Article  Google Scholar 

  66. Baggstrom MQ, et al. A phase II study of AT-101 (gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J Thorac Oncol. 2011;6(10):1757–60.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Souers AJ, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–8.

    Article  CAS  PubMed  Google Scholar 

  68. Peperzak V, et al. Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling. Cell Death Differ. 2016;24(1):111–9. doi:10.1038/cdd.2016.105.

  69. Montero J, et al. Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL-2 and sensitive to venetoclax. Cancer Discov. 2017;7(2):156–64. doi:10.1158/2159-8290.cd-16-0999.

  70. Ryan J, et al. iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry. Biol Chem. 2016;397(7):671.

    Article  CAS  PubMed  Google Scholar 

  71. Sharma SK, et al. A DLL3-targeted theranostic for small cell lung cancer: imaging a low density target with a site-specifically modified radioimmunoconjugate. J Nucl Med. 2016;57(supplement 2):50.

    Google Scholar 

  72. • Strosberg J, et al. NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with 177Lu-Dotatate: efficacy and safety results. J Nucl Med. 2016;57(supplement 2):629. Landmark PRRT trial in low-grade neuroendocrine tumors. One caveat to comparisons to high-grade neuroendocrine tumors is that imaging may not correlate as closely to SSTR2 expression in SCLC due to inflammatory infiltrate and milieu.

    Google Scholar 

  73. Sollini M, et al. Brief report on the use of radiolabeled somatostatin analogs for the diagnosis and treatment of metastatic small-cell lung cancer patients. J Thorac Oncol. 2013;8(8):1095–101.

    Article  CAS  PubMed  Google Scholar 

  74. Lapa C, et al. Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy. Oncotarget. 2016;7(15):20033–40.

    PubMed  PubMed Central  Google Scholar 

  75. Dalm SU, et al. Comparison of the therapeutic response to treatment with a 177Lu-labeled somatostatin receptor agonist and antagonist in preclinical models. J Nucl Med. 2016;57(2):260–5.

    Article  CAS  PubMed  Google Scholar 

  76. Daniel VC, et al. A primary xenograft model of small cell lung cancer reveals irreversible changes in gene expression imposed by culture in-vitro. Cancer Res. 2009;69(8):3364.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. • Anderson WC, et al. Initiation and characterization of small cell lung cancer patient-derived xenografts from ultrasound-guided transbronchial needle aspirates. PLoS One. 2015;10(5):e0125255. These two papers and previous work with PDXs in SCLC will be vital to overcoming challenges with acquiring sufficient tissue for research.

    Article  PubMed  PubMed Central  Google Scholar 

  78. • Leong TL, et al. Genomic characterisation of small cell lung cancer patient-derived xenografts generated from endobronchial ultrasound-guided transbronchial needle aspiration specimens. PLoS One. 2014;9(9):e106862. These two papers and previous work with PDXs in SCLC will be vital to overcoming challenges with acquiring sufficient tissue for research.

    Article  PubMed  PubMed Central  Google Scholar 

  79. • Rothwell DG, et al. Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample. Mol Oncol. 2016;10(4):566–74. Falls into the same theme of broadening available tissue and genetic resources for SCLC.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Udyavar AR, et al. Novel hybrid phenotype revealed in small cell lung cancer by a transcription factor network model that can explain tumor heterogeneity. Cancer Res. 2017;77(5):1063–74. doi:10.1158/0008-5472.can-16-1467.

  81. • Tirosh I, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352(6282):189–96. Pivotal single cell RNA seq study in cancer. Limited somewhat by efficiency and time required per cell sequence, but the technology and efficiency are improving quickly.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. • Leelatian N, et al. Single cell analysis of human tissues and solid tumors with mass cytometry. Cytometry B Clin Cytom. 2016; First publication with single cell mass cytometry data on SCLC. This technique will allow for characterization of phospho and protein expression at 40+ dimensions at the single cell level in SCLC. This is particularly relevant as is single cell RNAseq given concerns about expression level and epigenetic changes contributing to heterogeneity in SCLC.

Download references

Acknowledgements

Jonathan M. Lehman would like to acknowledge the LUNGevity foundation for career development support. Jonathan M. Lehman and Pierre P. Massion gratefully acknowledge Veterans Affairs research support to Pierre P. Massion via VA merit I01CX001425-01.

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, 2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN, 37232, USA

    Jonathan M. Lehman

  2. Vanderbilt University, PMB 353746, 2301 Vanderbilt Place, Nashville, TN, 37235, USA

    Mary E. Gwin

  3. Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, 2220 Pierce Avenue, Preston Research Building, 640, Nashville, TN, USA

    Pierre P. Massion

  4. Cancer Early Detection and Prevention Initiative, Vanderbilt-Ingram Cancer Center, 2220 Pierce Avenue, Nashville, TN, 37232, USA

    Pierre P. Massion

  5. US Department of Veterans Affairs, Tennessee Valley Healthcare System, 1310 24th Avenue South, Nashville, TN, 37212, USA

    Pierre P. Massion

Authors
  1. Jonathan M. Lehman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mary E. Gwin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pierre P. Massion
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pierre P. Massion.

Ethics declarations

Conflict of Interest

Jonathan M. Lehman’s institution receives funding from Abbvie/StemCentrx for a trial for which he is a co-investigator, and IPSEN for an upcoming pre-clinical study directed by him.

Mary E. Gwin and Pierre P. Massion declare they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Lung Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lehman, J.M., Gwin, M.E. & Massion, P.P. Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope. Curr Oncol Rep 19, 49 (2017). https://doi.org/10.1007/s11912-017-0609-2

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-017-0609-2

Keywords

Search

Navigation